Adalimumab biosimilar - Shanghai Henlius Biotech

Drug Profile

Adalimumab biosimilar - Shanghai Henlius Biotech

Alternative Names: HLX 03

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 04 Dec 2017 Adalimumab biosimilar is still in phase I trials for Rheumatoid arthritis in China (NCT03357939)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (Parenteral, Injection)
  • 01 Oct 2017 Phase-III clinical trials in Plaque psoriasis in China (SC) (NCT03316781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top